# Ansa Biotechnologies

Canonical page: https://technooptimist.io/companies/ansa-biotechnologies
Emeryville, California company that writes DNA with an enzyme instead of harsh chemistry, selling sequence-perfect DNA up to 50,000 bases long for gene therapy, antibody and synthetic-biology work.

## In brief

- Sells clonal DNA up to 50 kb, which it calls the longest sequence-perfect synthetic DNA on the market (Oct 2025).
- Direct enzymatic synthesis of fragments up to 900 bases; chemically made constructs rarely exceed 10 kb.
- Raised $68M Series A (2022) and $54.4M Series B (2025); manufactures only in the US.

## Facts

- Headquarters: US
- Status: private
- Raised: $122M
- Website: https://www.ansabio.com
- Frontiers: [Biotech](https://technooptimist.io/biotech.md) (Synthetic biology)

## Programs

- [Enzymatic long-DNA synthesis](https://technooptimist.io/biotech/enzymatic-dna-synthesis.md) (Biotech): Scaling; next: Scaling capacity and product range (vectors, larger scale) (2026). Selling 50 kb sequence-perfect clonal DNA since Oct 2025, delivered in under 25 business days.

## Latest updates

- **22 Oct 2025**: Ansa launches 50 kb sequence-perfect clonal DNA, the longest synthetic DNA sold commercially. After an early-access programme with more than 20 institutions, Ansa launched clonal DNA constructs up to 50,000 bases, verified by long-read sequencing and delivered in under 25 business days. ([our story](https://technooptimist.io/stories/ansa-launches-50-kb-sequence-perfect-clonal-dna-the-longest-synthetic-7b6568a2.md) · [original source](https://www.drugdiscoverynews.com/ansa-biotechnologies-redefines-what-s-possible-in-dna-synthesis-with-50-kb-sequence-perfect-clonal-product-16751))
- **1 Oct 2025**: Ansa raises $54.4M Series B led by Cerberus Ventures to expand US DNA manufacturing. Ansa closed $45.2M with $9.2M more committed, a $54.4M Series B led by Cerberus Ventures, to expand US manufacturing capacity. ([our story](https://technooptimist.io/stories/ansa-raises-54-4m-series-b-led-by-cerberus-ventures-to-expand-us-dna-96cfd72f.md) · [original source](https://www.biospace.com/press-releases/ansa-biotechnologies-secures-54-4-million-in-series-b-financing-to-redefine-how-scientists-access-synthetic-dna-with-industrys-first-guaranteed-on-time-service))
- **11 Apr 2022**: Ansa Biotechnologies closes $68M Series A to commercialise enzymatic DNA synthesis. Ansa raised a $68M Series A led by Northpond Ventures to build high-throughput synthesizers and launch a DNA synthesis service. ([our story](https://technooptimist.io/stories/ansa-biotechnologies-closes-68m-series-a-to-commercialise-enzymatic-dna-93d12f67.md) · [original source](https://www.biospace.com/article/releases/ansa-biotechnologies-closes-oversubscribed-68-million-series-a-financing-to-power-the-next-era-of-dna-enabled-industries))

## Funding

| Date | Round | Amount | Post-money | Leads |
| --- | --- | --- | --- | --- |
| 1 Oct 2025 | Series B | $54M |   | Cerberus Ventures |
| 11 Apr 2022 | Series A | $68M |   | Northpond Ventures |

## Partners, customers and investors

- Microsoft (partner): Collaborated on enzymatic reagents for DNA-based data storage (announced 2021).

## People

- Jason T. Gammack, Chief Executive Officer
- Daniel Lin-Arlow, Co-founder
- Sebastian Palluk, Co-founder

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.